WGO Graded Evidence: Osteoporosis

Level: Meta-analyses, Systematic reviews, Practice guidelines: 20 Abstracts

Legend:   : Special Mention  : Important  : Very Important  : Key Development
	Do guidelines matter? Implementation of the ACG and AGA osteoporosis screening guidelines in inflammatory bowel disease (IBD) patients who meet the guidelines' criteria. A Kornbluth, M Hayes, S Feldman, M Hunt, E Fried-Boxt, S Lichtiger, P Legnani, J George, J Young, Am J Gastroenterol. 2006 Jul:1546-50
	Fracture risk in people with primary biliary cirrhosis: a population-based cohort study. M Solaymani-Dodaran, TR Card, GP Aithal, J West, Gastroenterology. 2006 Dec:1752-7
	Inflammation is the main determinant of low bone mineral density in pediatric inflammatory bowel disease. M Paganelli, C Albanese, O Borrelli, F Civitelli, N Canitano, F Viola, R Passariello, S Cucchiara, Inflamm Bowel Dis. 2007 Apr:416-23
	Intravenous pamidronate in combination with calcium and vitamin D: highly effective in the treatment of low bone mineral density in inflammatory bowel disease. PC Stokkers, M Deley, M Van Der Spek, HJ Verberne, SJ Van Deventer, DW Hommes, Scand J Gastroenterol. 2006 Feb:200-4
	Susceptibility-guided vs. empiric retreatment of Helicobacter pylori infection after treatment failure. J Yahav, Z Samra, Y Niv, CT Evans, DJ Passaro, G Dinari, H Shmuely, Dig Dis Sci. 2006 Dec:2316-21
	Bone loss in Crohn's disease: exercise as a potential countermeasure. N Lee, G Radford-Smith, DR Taaffe, Inflamm Bowel Dis. 2005 Dec:1108-18
	Bones and Crohn's: risk factors associated with low bone mineral density in patients with Crohn's disease. JS Siffledeen, RN Fedorak, K Siminoski, H Jen, E Vaudan, N Abraham, H Seinhart, G Greenberg, Inflamm Bowel Dis. 2004 May:220-8
	Changes of OPG and RANKL concentrations in Crohn's disease after infliximab therapy. P Miheller, G Muzes, K Rácz, A Blázovits, P Lakatos, L Herszényi, Z Tulassay, Inflamm Bowel Dis. 2007 Nov:1379-84
	Guidelines do help change behavior in the management of osteoporosis by gastroenterologists. S Kane, D Reddy, Am J Gastroenterol. 2006 Aug:1841-4
	Hyperhomocysteinaemia is associated with osteoporosis in patients with Crohn's disease. X Roblin, JM Phelip, M Genevois, V Ducros, B Bonaz, Aliment Pharmacol Ther. 2007 Apr 1:797-804
	IBD and skeletal health: children are not small adults! FA Sylvester, Inflamm Bowel Dis. 2005 Nov:1020-3
	The RANKL/OPG system is activated in inflammatory bowel disease and relates to the state of bone loss. AR Moschen, A Kaser, B Enrich, O Ludwiczek, M Gabriel, P Obrist, AM Wolf, H Tilg, Gut. 2005 Apr:479-87
	Tumor necrosis factor-alpha haplotype is strongly associated with bone mineral density in patients with Crohn's disease. N Lee, E Fowler, S Mason, D Lincoln, DR Taaffe, G Radford-Smith, J Gastroenterol Hepatol. 2007 Jun:913-9
Supplementary evidence:
	AGA technical review on osteoporosis in gastrointestinal diseases. CN Bernstein, WD Leslie, MS Leboff, Gastroenterology. 2003 Mar:795-841
	AGA technical review on osteoporosis in hepatic disorders. WD Leslie, CN Bernstein, MS Leboff, American Gastroenterological Association Clinical Practice Commitee, Gastroenterology. 2003 Sep:941-66
	American Gastroenterological Association medical position statement: guidelines on osteoporosis in gastrointestinal diseases. [No Authors Listed], Gastroenterology. 2003 Mar:791-4
	Calcium intake and osteoporosis H Orimo, Clin Calcium. 2004 Nov:108-10
	Guidelines on the management of osteoporosis associated with chronic liver disease. JD Collier, M Ninkovic, JE Compston, Gut. 2002 Feb:i1-9
	Prevention and treatment of osteoporosis in inflammatory bowel disease. GR Lichtenstein, BE Sands, M Pazianas, Inflamm Bowel Dis. 2006 Aug:797-813
	Treatment of bone disorders in liver disease. A Parés, N Guañabens, J Hepatol. 2006 Sep:445-53